An anesthetized model of lethal canine galactosamine fulminant hepatic failure

Timothy D. Sielaff; Michael Y. Hu; Mark D. Rollins; Joseph R. Bloomer; Bruce Amiot; Wei Shou Hu; Frank B. Cerra

doi:10.1016/0270-9139(95)90534-0

An anesthetized model of lethal canine galactosamine fulminant hepatic failure

Timothy D. Sielaff, Michael Y. Hu, Mark D. Rollins, Joseph R. Bloomer, Bruce Amiot, Wei Shou Hu, Frank B. Cerra

Chemical Engineering and Materials Science

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

A reproducible large animal model of fulminant hepatic failure was developed in the anesthetized dog by the administration of the amino sugar D-galactosamine. Galactosamine in 5% dextrose in water (D₅W), was given as an intravenous bolus to 10 young male dogs weighing 27 to 30 kg. Three dogs that received an equal volume of D₅W alone served as controls. Galactosamine at 0.5 g/ kg (n = 5) produced significant biochemical evidence of liver injury with 100% survival at 48 hours. Galactosamine 1.0 g/kg (n = 5) yielded in 100% 48-hour mortality resulting from fulminant liver failure characterized by a progressive increase in liver enzymes, total bilirubin, ammonia, and lactate and associated coagulopathy, hypoglycemia, coma, and increased intracranial pressure. Necropsy showed liver pallor, ascites, and brain swelling. Liver histology showed significant hepatocellular necrosis. This clinically relevant large animal model will enable the quantitative evaluation of new technologies, such as the bioartificial liver, for the support of hepatic failure in humans.

Original language	English (US)
Pages (from-to)	796-804
Number of pages	9
Journal	Hepatology
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/0270-9139(95)90534-0
State	Published - Mar 1995

Bibliographical note

Funding Information:
Abbreviations: FHF, fulminant hepatic failure; IV, intravenous. From the Departments of 1Surgery, 2Medicine, and 4Chemical Engineering and Materials Sciences, University of Minnesota, Minneapolis; and 3Cellex Biosciences, Coon Rapids, MN. Received January 10, 1994; accepted October 4, 1994. Supported by a grant from Cellex Biosciences, Coon Rapids, MN. Address reprint requests to: Frank B. Cerra, MD, Professor of Surgery, Department of Surgery, University of Minnesota Hospitals and Clinic, Box 42, Minneapolis, MN 55455. Copyright © 1995 by the American Association for the Study of Liver Diseases. 0270-9139/95/2103-002853.00/0

Access

10.1016/0270-9139(95)90534-0

OpenUrl availability

Full text

Cite this

@article{018104c482db42829467c4b808fcff2b,

title = "An anesthetized model of lethal canine galactosamine fulminant hepatic failure",

abstract = "A reproducible large animal model of fulminant hepatic failure was developed in the anesthetized dog by the administration of the amino sugar D-galactosamine. Galactosamine in 5% dextrose in water (D5W), was given as an intravenous bolus to 10 young male dogs weighing 27 to 30 kg. Three dogs that received an equal volume of D5W alone served as controls. Galactosamine at 0.5 g/ kg (n = 5) produced significant biochemical evidence of liver injury with 100% survival at 48 hours. Galactosamine 1.0 g/kg (n = 5) yielded in 100% 48-hour mortality resulting from fulminant liver failure characterized by a progressive increase in liver enzymes, total bilirubin, ammonia, and lactate and associated coagulopathy, hypoglycemia, coma, and increased intracranial pressure. Necropsy showed liver pallor, ascites, and brain swelling. Liver histology showed significant hepatocellular necrosis. This clinically relevant large animal model will enable the quantitative evaluation of new technologies, such as the bioartificial liver, for the support of hepatic failure in humans.",

author = "Sielaff, {Timothy D.} and Hu, {Michael Y.} and Rollins, {Mark D.} and Bloomer, {Joseph R.} and Bruce Amiot and Hu, {Wei Shou} and Cerra, {Frank B.}",

note = "Funding Information: Abbreviations: FHF, fulminant hepatic failure; IV, intravenous. From the Departments of 1Surgery, 2Medicine, and 4Chemical Engineering and Materials Sciences, University of Minnesota, Minneapolis; and 3Cellex Biosciences, Coon Rapids, MN. Received January 10, 1994; accepted October 4, 1994. Supported by a grant from Cellex Biosciences, Coon Rapids, MN. Address reprint requests to: Frank B. Cerra, MD, Professor of Surgery, Department of Surgery, University of Minnesota Hospitals and Clinic, Box 42, Minneapolis, MN 55455. Copyright {\textcopyright} 1995 by the American Association for the Study of Liver Diseases. 0270-9139/95/2103-002853.00/0",

year = "1995",

month = mar,

doi = "10.1016/0270-9139(95)90534-0",

language = "English (US)",

volume = "21",

pages = "796--804",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - An anesthetized model of lethal canine galactosamine fulminant hepatic failure

AU - Sielaff, Timothy D.

AU - Hu, Michael Y.

AU - Rollins, Mark D.

AU - Bloomer, Joseph R.

AU - Amiot, Bruce

AU - Hu, Wei Shou

AU - Cerra, Frank B.

N1 - Funding Information: Abbreviations: FHF, fulminant hepatic failure; IV, intravenous. From the Departments of 1Surgery, 2Medicine, and 4Chemical Engineering and Materials Sciences, University of Minnesota, Minneapolis; and 3Cellex Biosciences, Coon Rapids, MN. Received January 10, 1994; accepted October 4, 1994. Supported by a grant from Cellex Biosciences, Coon Rapids, MN. Address reprint requests to: Frank B. Cerra, MD, Professor of Surgery, Department of Surgery, University of Minnesota Hospitals and Clinic, Box 42, Minneapolis, MN 55455. Copyright © 1995 by the American Association for the Study of Liver Diseases. 0270-9139/95/2103-002853.00/0

PY - 1995/3

Y1 - 1995/3

N2 - A reproducible large animal model of fulminant hepatic failure was developed in the anesthetized dog by the administration of the amino sugar D-galactosamine. Galactosamine in 5% dextrose in water (D5W), was given as an intravenous bolus to 10 young male dogs weighing 27 to 30 kg. Three dogs that received an equal volume of D5W alone served as controls. Galactosamine at 0.5 g/ kg (n = 5) produced significant biochemical evidence of liver injury with 100% survival at 48 hours. Galactosamine 1.0 g/kg (n = 5) yielded in 100% 48-hour mortality resulting from fulminant liver failure characterized by a progressive increase in liver enzymes, total bilirubin, ammonia, and lactate and associated coagulopathy, hypoglycemia, coma, and increased intracranial pressure. Necropsy showed liver pallor, ascites, and brain swelling. Liver histology showed significant hepatocellular necrosis. This clinically relevant large animal model will enable the quantitative evaluation of new technologies, such as the bioartificial liver, for the support of hepatic failure in humans.

AB - A reproducible large animal model of fulminant hepatic failure was developed in the anesthetized dog by the administration of the amino sugar D-galactosamine. Galactosamine in 5% dextrose in water (D5W), was given as an intravenous bolus to 10 young male dogs weighing 27 to 30 kg. Three dogs that received an equal volume of D5W alone served as controls. Galactosamine at 0.5 g/ kg (n = 5) produced significant biochemical evidence of liver injury with 100% survival at 48 hours. Galactosamine 1.0 g/kg (n = 5) yielded in 100% 48-hour mortality resulting from fulminant liver failure characterized by a progressive increase in liver enzymes, total bilirubin, ammonia, and lactate and associated coagulopathy, hypoglycemia, coma, and increased intracranial pressure. Necropsy showed liver pallor, ascites, and brain swelling. Liver histology showed significant hepatocellular necrosis. This clinically relevant large animal model will enable the quantitative evaluation of new technologies, such as the bioartificial liver, for the support of hepatic failure in humans.

UR - http://www.scopus.com/inward/record.url?scp=0028939262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028939262&partnerID=8YFLogxK

U2 - 10.1016/0270-9139(95)90534-0

DO - 10.1016/0270-9139(95)90534-0

M3 - Article

C2 - 7875678

AN - SCOPUS:0028939262

SN - 0270-9139

VL - 21

SP - 796

EP - 804

JO - Hepatology

JF - Hepatology

IS - 3

ER -

An anesthetized model of lethal canine galactosamine fulminant hepatic failure

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this